Pegylated liposomal doxorubicin treatment in patients with refractory or relapsed central nervous system (CNS) lymphoma.

被引：0
|
作者：
Calvisi, A [1 ]
Palmas, AD [1 ]
Lai, P [1 ]
Bianchi, A [1 ]
Murgia, A [1 ]
Gaviano, E [1 ]
Noli, AL [1 ]
Curreli, L [1 ]
Gabbas, A [1 ]
机构：
[1] San Francisco Hosp, Hematol & BMT Ctr, Nuoro, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4750
引用
收藏
页码：302B / 303B
页数：2
相关论文
共 50 条
  • [31] A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
    Westin, Jason R.
    Fowler, Nathan H.
    Nastoupil, Loretta J.
    Neelapu, Sattva S.
    Lee, Hun Ju
    Hagemeister, Fredrick B.
    Rodriguez, Maria Alma
    Steiner, Raphael E.
    Ahmed, Sairah
    Parmar, Simrit
    Nair, Ranjit
    Harrison, Rebecca
    Fayad, Luis
    [J]. BLOOD, 2019, 134
  • [32] Use of pegylated liposomal doxorubicin in patients with lymphoma and contraindications for anthracyclines
    Balensiefer, B.
    Christofyllakis, B.
    Bewarder, Y.
    Kaddu-Mulindwa, D.
    Thurner, L.
    Bittenbring, J. T.
    Ahlgrimm, M.
    Bewarder, M.
    Boehm, M.
    Stilgenbauer, S.
    Christofyllakis, K.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 193 - 193
  • [33] Liposomal doxorubicin in the treatment of lymphoma patients
    Mappa, S.
    Rigacci, L.
    Nassi, L.
    Puccini, B.
    Alterini, R.
    Carrai, V
    Bernardi, F.
    Bosi, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 61 - 61
  • [34] A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
    Schroeder, Mark A.
    Fiala, Mark A.
    Huselton, Eric
    Cardone, Michael H.
    Jaeger, Savina
    Jean, Sae Rin
    Shea, Kathryn
    Ghobadi, Armin
    Wildes, Tanya
    Stocked-Goldstein, Keith E.
    Vij, Ravi
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3776 - 3783
  • [35] Liposomal doxorubicin-liposomal doxorubicin-rituximab for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Zaja, F
    Tomadini, V
    Zaccaria, A
    Lauria, F
    Molinari, AL
    Fabbri, A
    Battista, R
    Angelucci, E
    Gallamini, A
    Battista, M
    Fanin, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 606S - 606S
  • [36] A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Hilger, James D.
    Klein, Leonard M.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2012, 120 (21)
  • [37] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    Berenson, J. R.
    Yellin, O.
    Kazamel, T.
    Hilger, J. D.
    Chen, C-S
    Cartmell, A.
    Woliver, T.
    Flam, M.
    Bravin, E.
    Nassir, Y.
    Vescio, R.
    Swift, R. A.
    [J]. LEUKEMIA, 2012, 26 (07) : 1675 - 1680
  • [38] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2014, 124 (21)
  • [39] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [40] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    J R Berenson
    O Yellin
    T Kazamel
    J D Hilger
    C-S Chen
    A Cartmell
    T Woliver
    M Flam
    E Bravin
    Y Nassir
    R Vescio
    R A Swift
    [J]. Leukemia, 2012, 26 : 1675 - 1680
12345